Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 6/20 | 0.35 |
| ▸ | FABP5 | Q01469 | 6/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.34 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.34 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.34 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15998536 | 0.84 | CHRM2 (0.37) | CHRM2CRHR1 | |
| SCHEMBL2727124 | 0.79 | CHRM2 (0.34) | FABP4FABP5CHRM2CRHR1 | |
| SCHEMBL23588266 | 0.68 | CHRM2 (0.36) | FABP4FABP5HDAC3HDAC4HDAC1 | |
| SCHEMBL12904914 | 0.67 | CHRM2 (0.35) | CHRM2CRHR1 | |
| Trifluoroacetic Acid SCHEMBL22615378 | 0.66 | F10 (0.32) | — | |
| SCHEMBL22629017 | 0.65 | KDM1A (0.43) | FABP4FABP5CHRM2 | |
| SCHEMBL22347897 | 0.65 | HSD11B1 (0.43) | CHRM2 | |
| SCHEMBL23588192 | 0.64 | CHRM2 (0.33) | FABP4FABP5CHRM2 | |
| SCHEMBL22395041 | 0.64 | CHRM2 (0.33) | FABP4FABP5CHRM2 | |
| SCHEMBL22629019 | 0.63 | HSD11B1 (0.35) | FABP4FABP5CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220306647-A1 | NOVEL INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITUS B VIRUS (HBV) | AICURIS GMBH & CO. KG (DE) | 2022-09-29 | — | — | US | disclosed |
| EP-3962914-A1 | NOVEL INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AiCuris GmbH & Co. KG (DE) | 2022-03-09 | — | — | EP | disclosed |
| US-11236087-B2 | Highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis B virus (HBV) | AICURIS GMBH & CO. KG (DE) | 2022-02-01 | — | — | US | disclosed |
| US-20210179608-A1 | NOVEL, HIGHLY ACTIVE PYRAZOLO-PIPERIDINE SUBSTITUTED INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AICURIS GMBH & CO. KG (DE) | 2021-06-17 | — | — | US | disclosed |
| CN-111527087-A | Novel highly active pyrazolo-piperidine substituted indole-2-carboxamides having activity against Hepatitis B Virus (HBV) | 艾库里斯有限及两合公司 | 2020-08-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210179608-A1 | NOVEL, HIGHLY ACTIVE PYRAZOLO-PIPERIDINE SUBSTITUTED INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | CDK2, HCCS, BRD4 | FABP4 4082/4885FABP5 860/4885HDAC3 164/4885 |
| US-20220306647-A1 | NOVEL INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITUS B VIRUS (HBV) | HCCS, IDO1, BRD4 | FABP4 2702/4885FABP5 474/4885HDAC3 263/4885 |
| US-11236087-B2 | Highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis B virus (HBV) | HCCS, BRD4, CDK2 | FABP4 4129/4885FABP5 828/4885HDAC3 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.